Matches in SemOpenAlex for { <https://semopenalex.org/work/W15164276> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W15164276 endingPage "110" @default.
- W15164276 startingPage "106" @default.
- W15164276 abstract "Summary Forskolin, a plant (Coleus forskohlii) diterpene, inhibits ADP- induced (human: IC50, 2.3±1.0 μ;M; rat: IC50, 1.2±0.5 μM) and collagen-induced (human: IC50, 2.4±1.2 μM; rat: 0.6±0.2 μM) platelet aggregation in human and rat platelet-rich plasma (PRP). Human blood levels of adenosine (Ado) are low (100-300 nM) as compared to levels in rat plasma (7.55 ± 0.51 μM). Ado is a natural antiplatelet and vasodilatory agent produced by vascular endothelium, heart and other body tissues. If the plasma Ado is degraded by pretreatment of PRP with adenosine deaminase (ADA), forskolin inhibition on platelet aggregation is reduced by 2-4 fold both in human and rat blood. On the other hand, if the physiological steady state levels of Ado are maintained by collecting the blood in the presence of the inhibitors of ADA (2’-deoxycoformycin, dCF, 5 μM) and Ado uptake (dipyridamole, 10 μM or dilazep, 2 μM), forskolin inhibition (IC50, 3.2 μM) on platelet aggregation in human PRP is potentiated by 20-40 fold (IC50, 0.075-0.15 μM). Similar potentiated forskolin effect (IC50, 0.53 μM) is seen if the ADA-treated human PRP is replenished with a low level of Ado (50 nM) after ADA inactivation by dCF and Ado-uptake blockade by dilazep. If the plasma is replenished with a higher concentration of Ado (300 nM), greater potentiation is seen (IC50, 0.23 μM). Forskolin is 2-4 fold more inhibitory in rat PRP than in human PRP, partially due to the presence of higher levels of Ado in the rat plasma. These studies demonstrate an important role of plasma Ado in the antiplatelet activity of forskolin and this effect can be greatly potentiated by the clinically used drugs, dipyridamole and dilazep." @default.
- W15164276 created "2016-06-24" @default.
- W15164276 creator A5007920808 @default.
- W15164276 creator A5042272424 @default.
- W15164276 creator A5078821665 @default.
- W15164276 date "1989-01-01" @default.
- W15164276 modified "2023-09-26" @default.
- W15164276 title "Significance of Plasma Adenosine in the Antiplatelet Activity of Forskolin: Potentiation by Dipyridamole and Dilazep" @default.
- W15164276 doi "https://doi.org/10.1055/s-0038-1646536" @default.
- W15164276 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2749584" @default.
- W15164276 hasPublicationYear "1989" @default.
- W15164276 type Work @default.
- W15164276 sameAs 15164276 @default.
- W15164276 citedByCount "27" @default.
- W15164276 countsByYear W151642762012 @default.
- W15164276 countsByYear W151642762016 @default.
- W15164276 countsByYear W151642762017 @default.
- W15164276 countsByYear W151642762022 @default.
- W15164276 countsByYear W151642762023 @default.
- W15164276 crossrefType "journal-article" @default.
- W15164276 hasAuthorship W15164276A5007920808 @default.
- W15164276 hasAuthorship W15164276A5042272424 @default.
- W15164276 hasAuthorship W15164276A5078821665 @default.
- W15164276 hasConcept C126322002 @default.
- W15164276 hasConcept C134018914 @default.
- W15164276 hasConcept C170493617 @default.
- W15164276 hasConcept C185592680 @default.
- W15164276 hasConcept C202751555 @default.
- W15164276 hasConcept C25274449 @default.
- W15164276 hasConcept C2776890861 @default.
- W15164276 hasConcept C2776991684 @default.
- W15164276 hasConcept C2777752497 @default.
- W15164276 hasConcept C2779276759 @default.
- W15164276 hasConcept C2910277799 @default.
- W15164276 hasConcept C34628245 @default.
- W15164276 hasConcept C55493867 @default.
- W15164276 hasConcept C71924100 @default.
- W15164276 hasConcept C86803240 @default.
- W15164276 hasConcept C89560881 @default.
- W15164276 hasConcept C98274493 @default.
- W15164276 hasConceptScore W15164276C126322002 @default.
- W15164276 hasConceptScore W15164276C134018914 @default.
- W15164276 hasConceptScore W15164276C170493617 @default.
- W15164276 hasConceptScore W15164276C185592680 @default.
- W15164276 hasConceptScore W15164276C202751555 @default.
- W15164276 hasConceptScore W15164276C25274449 @default.
- W15164276 hasConceptScore W15164276C2776890861 @default.
- W15164276 hasConceptScore W15164276C2776991684 @default.
- W15164276 hasConceptScore W15164276C2777752497 @default.
- W15164276 hasConceptScore W15164276C2779276759 @default.
- W15164276 hasConceptScore W15164276C2910277799 @default.
- W15164276 hasConceptScore W15164276C34628245 @default.
- W15164276 hasConceptScore W15164276C55493867 @default.
- W15164276 hasConceptScore W15164276C71924100 @default.
- W15164276 hasConceptScore W15164276C86803240 @default.
- W15164276 hasConceptScore W15164276C89560881 @default.
- W15164276 hasConceptScore W15164276C98274493 @default.
- W15164276 hasIssue "01" @default.
- W15164276 hasLocation W151642761 @default.
- W15164276 hasLocation W151642762 @default.
- W15164276 hasOpenAccess W15164276 @default.
- W15164276 hasPrimaryLocation W151642761 @default.
- W15164276 hasRelatedWork W15164276 @default.
- W15164276 hasRelatedWork W2007885146 @default.
- W15164276 hasRelatedWork W2017770252 @default.
- W15164276 hasRelatedWork W2056270585 @default.
- W15164276 hasRelatedWork W2058991568 @default.
- W15164276 hasRelatedWork W206302104 @default.
- W15164276 hasRelatedWork W2284240597 @default.
- W15164276 hasRelatedWork W2320914227 @default.
- W15164276 hasRelatedWork W2398262967 @default.
- W15164276 hasRelatedWork W2414307609 @default.
- W15164276 hasVolume "61" @default.
- W15164276 isParatext "false" @default.
- W15164276 isRetracted "false" @default.
- W15164276 magId "15164276" @default.
- W15164276 workType "article" @default.